TR201815211T4 - Hücre kültüründe rekombinant adamts13 üretmeye yönelik yöntem. - Google Patents

Hücre kültüründe rekombinant adamts13 üretmeye yönelik yöntem.

Info

Publication number
TR201815211T4
TR201815211T4 TR2018/15211T TR201815211T TR201815211T4 TR 201815211 T4 TR201815211 T4 TR 201815211T4 TR 2018/15211 T TR2018/15211 T TR 2018/15211T TR 201815211 T TR201815211 T TR 201815211T TR 201815211 T4 TR201815211 T4 TR 201815211T4
Authority
TR
Turkey
Prior art keywords
cell culture
present
producing recombinant
recombinant adamts13
high specific
Prior art date
Application number
TR2018/15211T
Other languages
English (en)
Inventor
Grillberger Leopold
Reiter Manfred
Fleischanderl Daniel
Bramberger Gregor
Original Assignee
Baxalta GmbH
Baxalta Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=44514323&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=TR201815211(T4) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Baxalta GmbH, Baxalta Inc filed Critical Baxalta GmbH
Publication of TR201815211T4 publication Critical patent/TR201815211T4/tr

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/36—Blood coagulation or fibrinolysis factors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/36—Blood coagulation or fibrinolysis factors
    • A61K38/37—Factors VIII
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P33/00—Antiparasitic agents
    • A61P33/02—Antiprotozoals, e.g. for leishmaniasis, trichomoniasis, toxoplasmosis
    • A61P33/06—Antimalarials
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/04—Antihaemorrhagics; Procoagulants; Haemostatic agents; Antifibrinolytic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K1/00—General methods for the preparation of peptides, i.e. processes for the organic chemical preparation of peptides or proteins of any length
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/745—Blood coagulation or fibrinolysis factors
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/745—Blood coagulation or fibrinolysis factors
    • C07K14/755—Factors VIII, e.g. factor VIII C (AHF), factor VIII Ag (VWF)
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
    • C12N5/0018—Culture media for cell or tissue culture
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
    • C12N5/10—Cells modified by introduction of foreign genetic material
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
    • C12N9/14—Hydrolases (3)
    • C12N9/48—Hydrolases (3) acting on peptide bonds (3.4)
    • C12N9/50—Proteinases, e.g. Endopeptidases (3.4.21-3.4.25)
    • C12N9/64—Proteinases, e.g. Endopeptidases (3.4.21-3.4.25) derived from animal tissue
    • C12N9/6421—Proteinases, e.g. Endopeptidases (3.4.21-3.4.25) derived from animal tissue from mammals
    • C12N9/6489—Metalloendopeptidases (3.4.24)
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12P—FERMENTATION OR ENZYME-USING PROCESSES TO SYNTHESISE A DESIRED CHEMICAL COMPOUND OR COMPOSITION OR TO SEPARATE OPTICAL ISOMERS FROM A RACEMIC MIXTURE
    • C12P21/00—Preparation of peptides or proteins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2500/00—Specific components of cell culture medium
    • C12N2500/05—Inorganic components
    • C12N2500/10—Metals; Metal chelators
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2500/00—Specific components of cell culture medium
    • C12N2500/05—Inorganic components
    • C12N2500/10—Metals; Metal chelators
    • C12N2500/20—Transition metals
    • C12N2500/24—Iron; Fe chelators; Transferrin
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2501/00—Active agents used in cell culture processes, e.g. differentation
    • C12N2501/998—Proteins not provided for elsewhere
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2511/00—Cells for large scale production
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Y—ENZYMES
    • C12Y304/00—Hydrolases acting on peptide bonds, i.e. peptidases (3.4)
    • C12Y304/24—Metalloendopeptidases (3.4.24)
    • C12Y304/24087—ADAMTS13 endopeptidase (3.4.24.87)

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • General Health & Medical Sciences (AREA)
  • Zoology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Genetics & Genomics (AREA)
  • Medicinal Chemistry (AREA)
  • Wood Science & Technology (AREA)
  • Veterinary Medicine (AREA)
  • Biochemistry (AREA)
  • Biomedical Technology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Biotechnology (AREA)
  • Hematology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Molecular Biology (AREA)
  • General Engineering & Computer Science (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Microbiology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Epidemiology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Immunology (AREA)
  • Biophysics (AREA)
  • Toxicology (AREA)
  • Cell Biology (AREA)
  • Diabetes (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Dermatology (AREA)
  • Pain & Pain Management (AREA)
  • Rheumatology (AREA)
  • Analytical Chemistry (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)

Abstract

Diğer yönlerin arasında, mevcut buluş, yüksek molekül ağırlıklı vWF, özellikle, bir yüksek spesifik etkinliğe sahip yüksek multimerik WF ve bir yüksek spesifik etkinliğe sahip ADAMTS13 ile ilgilidir. Mevcut buluşun hücre kültür koşulları, örneğin, bir artırılmış bakır konsantrasyonuna sahip bir hücre kültür ortamı ve/veya düşük bir amonyum (NH4+) konsantrasyonuna sahip hücre kültür süpernatanı içerebilmektedir. Mevcut buluş aynı zamanda, yüksek molekül ağırlıklı vWF ve yüksek spesifik etkinliklere sahip rA13'ü ifade etmesi için hücre kültüründe hücrelerin yetiştirilmesine yönelik yöntemler sağlamaktadır.
TR2018/15211T 2010-07-08 2011-07-08 Hücre kültüründe rekombinant adamts13 üretmeye yönelik yöntem. TR201815211T4 (tr)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US36263510P 2010-07-08 2010-07-08

Publications (1)

Publication Number Publication Date
TR201815211T4 true TR201815211T4 (tr) 2018-11-21

Family

ID=44514323

Family Applications (1)

Application Number Title Priority Date Filing Date
TR2018/15211T TR201815211T4 (tr) 2010-07-08 2011-07-08 Hücre kültüründe rekombinant adamts13 üretmeye yönelik yöntem.

Country Status (25)

Country Link
US (8) US8852888B2 (tr)
EP (7) EP3064508B2 (tr)
JP (3) JP5953502B2 (tr)
KR (4) KR102007773B1 (tr)
CN (4) CN103097409A (tr)
AU (6) AU2011274467B2 (tr)
BR (1) BR112013000515B1 (tr)
CA (2) CA2804275A1 (tr)
CO (2) CO6680636A2 (tr)
DK (4) DK3626736T3 (tr)
EA (5) EA202090067A3 (tr)
ES (5) ES3037386T3 (tr)
FI (2) FI3064508T4 (tr)
HR (4) HRP20180136T1 (tr)
HU (4) HUE046443T2 (tr)
IL (5) IL223930A (tr)
MX (3) MX339632B (tr)
NZ (2) NZ605403A (tr)
PL (5) PL3064508T5 (tr)
PT (4) PT2590998T (tr)
SG (3) SG10201809632XA (tr)
SI (4) SI3626736T1 (tr)
TR (1) TR201815211T4 (tr)
TW (4) TWI670073B (tr)
WO (2) WO2012006591A1 (tr)

Families Citing this family (34)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ES2685503T3 (es) 2008-12-05 2018-10-09 Baxalta GmbH Métodos de medida de la división in vivo de Factor von Willebrand mediada por ADAMTS13 y utilización de los mismos
US8546548B2 (en) 2009-05-27 2013-10-01 Baxter International Inc. Method to produce a highly concentrated immunoglobulin preparation for subcutaneous use
AU2010202125B1 (en) 2010-05-26 2010-09-02 Takeda Pharmaceutical Company Limited A method to produce an immunoglobulin preparation with improved yield
US8772462B2 (en) 2010-05-26 2014-07-08 Baxter International Inc. Removal of serine proteases by treatment with finely divided silicon dioxide
EA202090067A3 (ru) * 2010-07-08 2020-07-31 Баксалта Инкорпорейтид Способ получения рекомбинантного adamts13 в культуре клеток
CN103732244A (zh) * 2011-06-10 2014-04-16 巴克斯特国际公司 通过施用重组vwf治疗凝血疾病
US9030963B2 (en) * 2012-12-03 2015-05-12 Honeywell International Inc. Analyzing a network topology
UY35343A (es) * 2013-02-26 2014-09-30 Bayer Healthcare Llc Formulaciones y procedimientos para la producción de proteína recombinante aumentada
US20140271622A1 (en) * 2013-03-14 2014-09-18 Momenta Pharmaceuticals, Inc. Methods of cell culture
US8956830B2 (en) 2013-03-14 2015-02-17 Momenta Pharmaceuticals, Inc. Methods of cell culture
US9677105B2 (en) 2013-03-14 2017-06-13 Momenta Pharmaceuticals, Inc. Methods of cell culture
US9217168B2 (en) 2013-03-14 2015-12-22 Momenta Pharmaceuticals, Inc. Methods of cell culture
AR095196A1 (es) * 2013-03-15 2015-09-30 Regeneron Pharma Medio de cultivo celular libre de suero
AU2013203062C1 (en) * 2013-03-15 2018-06-28 Takeda Pharmaceutical Company Limited Subcutaneous administration of adamts13
EP3131929B1 (en) * 2014-04-16 2022-06-01 INSERM (Institut National de la Santé et de la Recherche Médicale) Antibodies for the prevention or the treatment of bleeding episodes
EP3158055B1 (en) * 2014-06-13 2019-09-11 CSL Limited Improved production of recombinant von willebrand factor in a bioreactor
MA41685A (fr) * 2014-10-17 2017-08-22 Biogen Ma Inc Supplémentation en cuivre pour la régulation de la glycosylation dans un procédé de culture cellulaire de mammifère
EP3253884B1 (en) * 2015-02-05 2020-03-18 R.P. Scherer Technologies, LLC Activated formylglycine-generating enzymes and methods of producing and using the same
AR104050A1 (es) * 2015-03-26 2017-06-21 Chugai Pharmaceutical Co Ltd Proceso de producción con iones de cobre controlados
TW202440903A (zh) 2015-08-04 2024-10-16 美商再生元醫藥公司 補充牛磺酸之細胞培養基及用法（一）
US11191818B2 (en) 2016-08-04 2021-12-07 Takeda Pharmaceutical Company Limited Use of ADAMTS13 for treating, ameliorating and/or preventing vaso-occlusive crisis in sickle cell disease, acute lung injury and/or acute respiratory distress syndrome
CN106957815B (zh) * 2017-03-16 2021-05-07 杨涛 一种用于人类多潜能干细胞的无血清培养基的配方
FI3648788T5 (fi) 2017-07-07 2024-09-09 Takeda Pharmaceuticals Co Maha-suolikanavan verenvuodon hoito vaikeaa von willebrandin tautia sairastavilla potilailla antamalla rekombinanttia vwf:ää
JP7326246B2 (ja) 2017-07-07 2023-08-15 武田薬品工業株式会社 待機手術を受ける、重度のフォンヴィレブランド病を患う患者の、組換えｖｗｆの投与による治療法
CA3094644A1 (en) 2018-03-21 2019-09-26 Baxalta Incorporated Separation of vwf and vwf propeptide by chromatographic methods
EA202192140A1 (ru) 2019-02-01 2021-12-15 Такеда Фармасьютикал Компани Лимитед СПОСОБЫ ПРОФИЛАКТИЧЕСКОГО ЛЕЧЕНИЯ РЕКОМБИНАНТНЫМ ФВ (рФВ)
US11471497B1 (en) 2019-03-13 2022-10-18 David Gordon Bermudes Copper chelation therapeutics
US10961500B1 (en) 2019-04-23 2021-03-30 Regeneron Pharmaceuticals, Inc. Cell culture medium for eukaryotic cells
JP2022547556A (ja) 2019-09-11 2022-11-14 武田薬品工業株式会社 フォン・ヴィレブランド因子と補体ｃ１ｑの複合体に関連する治療法
US12661390B2 (en) 2019-10-04 2026-06-23 The Children's Medical Center Corporation ADAMTS13 treatment to enhance graft survival
US12297451B1 (en) 2019-10-25 2025-05-13 Regeneron Pharmaceuticals, Inc. Cell culture medium
CA3169996A1 (en) 2020-02-04 2021-08-12 Takeda Pharmaceutical Company Limited Treatment of menorrhagia in patients with severe von willebrand disease by administration of recombinant vwf
EP4150045A1 (en) * 2020-05-12 2023-03-22 PBS Biotech, Inc. Material transfer devices and related systems and methods
CN115835904A (zh) 2020-05-22 2023-03-21 武田药品工业有限公司 用于治疗和诊断冠状病毒疾病并发症的adamts13组合物和方法

Family Cites Families (50)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4767704A (en) * 1983-10-07 1988-08-30 Columbia University In The City Of New York Protein-free culture medium
US4797368A (en) 1985-03-15 1989-01-10 The United States Of America As Represented By The Department Of Health And Human Services Adeno-associated virus as eukaryotic expression vector
NL8500961A (nl) 1985-04-01 1986-11-03 Stichting Vrienden Van De Stic Cdna-codering voor de humane von willebrand-factor, plasmiden met een dergelijke cdna-codering respektievelijk fragmenten ervan, alsmede micro-organismen, welke dergelijke plasmiden bevatten.
WO1986006096A1 (en) 1985-04-11 1986-10-23 The Children's Medical Center Corporation Von willebrand factor
US5139941A (en) 1985-10-31 1992-08-18 University Of Florida Research Foundation, Inc. AAV transduction vectors
GB9022545D0 (en) 1990-10-17 1990-11-28 Wellcome Found Culture medium
ATE542891T1 (de) 1994-11-10 2012-02-15 Baxter Healthcare Sa Verfahren zur herstellung von biologischen produkten in protein-freier kultur
CA2211630A1 (en) 1995-02-23 1996-08-29 Quest International B.V. Peptides for tissue and cell culture media
US6013516A (en) 1995-10-06 2000-01-11 The Salk Institute For Biological Studies Vector and method of use for nucleic acid delivery to non-dividing cells
EP2221361A3 (en) 1996-08-30 2011-02-09 Life Technologies Corporation Method for producing a polypeptide in vitro in mammalian cells in a protein-free and serum-free culture medium
US6458574B1 (en) * 1996-09-12 2002-10-01 Transkaryotic Therapies, Inc. Treatment of a α-galactosidase a deficiency
US6103529A (en) 1996-10-10 2000-08-15 Life Technologies, Inc. Animal cell culture media comprising peptides derived from rice
WO1998041611A1 (en) 1997-03-20 1998-09-24 Regents Of The University Of Minnesota Process for the continuous culture of cells
US5804420A (en) 1997-04-18 1998-09-08 Bayer Corporation Preparation of recombinant Factor VIII in a protein free medium
AT407255B (de) 1997-06-20 2001-02-26 Immuno Ag Rekombinanter zellklon mit erhöhter stabilität in serum- und proteinfreiem medium und verfahren zur gewinnung des stabilen zellklons
US6475725B1 (en) 1997-06-20 2002-11-05 Baxter Aktiengesellschaft Recombinant cell clones having increased stability and methods of making and using the same
US5994136A (en) 1997-12-12 1999-11-30 Cell Genesys, Inc. Method and means for producing high titer, safe, recombinant lentivirus vectors
US6531577B1 (en) 1997-12-15 2003-03-11 Hemasure Denmark A/S von Willebrand factor (vWF)-containing preparation, process for preparing vWF-containing preparations, and use of such preparations
US6528286B1 (en) 1998-05-29 2003-03-04 Genentech, Inc. Mammalian cell culture process for producing glycoproteins
US6406909B1 (en) 1998-07-10 2002-06-18 Chugai Seiyaku Kabushiki Kaisha Serum-free medium for culturing animal cells
AT409379B (de) 1999-06-02 2002-07-25 Baxter Ag Medium zur protein- und serumfreien kultivierung von zellen
JP2001120262A (ja) * 1999-10-26 2001-05-08 Welfide Corp 生理活性物質の産生増強方法
US6926894B2 (en) * 2000-11-22 2005-08-09 Baxter Aktiengesellschaft Composition exhibiting a von willebrand factor (vWF) protease activity comprising a polypeptide chain with the amino acid sequence AAGGILHLELLV
US20050069979A1 (en) * 2001-11-28 2005-03-31 Steffen Zeng Cell culture process
CN1296485C (zh) * 2002-01-17 2007-01-24 英国龙沙生物医药股份有限公司 能够产生蛋白质及能够在无谷氨酰胺的培养基上生长的谷氨酰胺营养缺陷型人类细胞
US20050084828A1 (en) 2003-10-21 2005-04-21 The University Of North Carolina At Chapel Hill Apparatus and method for braille instruction
EP1593388A1 (en) 2004-05-05 2005-11-09 ZLB Behring GmbH Therapeutic plasma protein-concentrates containing von willebrand factor as high molecular weight multimers
US7294484B2 (en) * 2004-08-27 2007-11-13 Wyeth Research Ireland Limited Production of polypeptides
US20060094104A1 (en) 2004-10-29 2006-05-04 Leopold Grillberger Animal protein-free media for cultivation of cells
US8273553B2 (en) 2004-11-02 2012-09-25 Ares Trading S.A. Production of growth hormone in serum-free cell culture medium for mammalian cells
ES2361559T3 (es) * 2004-11-02 2011-06-20 Ares Trading S.A. Medio de cultivo de células exento de suero para mamíferos.
US20070049557A1 (en) 2005-08-24 2007-03-01 Hashim Ahmed Solid pharmaceutical dosage forms comprising bisphosphonates and modified amino acid carriers
ES2474573T3 (es) * 2006-01-04 2014-07-09 Baxter International Inc Medio de cultivo celular sin oligop�ptidos
US20070190057A1 (en) * 2006-01-23 2007-08-16 Jian Wu Methods for modulating mannose content of recombinant proteins
CN101490239A (zh) * 2006-07-14 2009-07-22 帝斯曼知识产权资产管理有限公司 改进的细胞培养方法
TW201516149A (zh) * 2006-09-13 2015-05-01 Abbvie Inc 細胞培養改良
US7960869B2 (en) 2006-09-22 2011-06-14 Siemens Industry, Inc. Internal intelligence for remote operated relay
MX2009007145A (es) 2006-12-27 2009-08-27 Nektar Therapeutics Al Corp Conjugados de polimero con factor viii y factor de von willebrand que tienen una ligadura liberable.
CA2679941C (en) * 2007-03-02 2016-09-20 Wyeth Use of copper and glutamate in cell culture for production of polypeptides
DE102007046611A1 (de) * 2007-09-28 2009-04-02 Osram Opto Semiconductors Gmbh Lichtquelle mit Konversionselement und Lichtwellenleiter, Verfahren zur Herstellung der Lichtquelle und deren Verwendung
SI2574677T1 (sl) * 2007-12-27 2017-11-30 Baxalta GmbH Procesi celične kulture
SG192471A1 (en) 2007-12-31 2013-08-30 Baxter Int Substantially animal protein-free recombinant furin and methods for producing same
JP4458167B2 (ja) * 2008-01-11 2010-04-28 住友金属工業株式会社 熱間塑性加工用潤滑剤を用いる継目無管製造における外面潤滑方法
WO2009116044A2 (en) 2008-03-19 2009-09-24 Yissum Research Development Company Of The Hebrew University Of Jerusalem Ltd. Compounds for treating bacterial infections
AU2009236187B2 (en) * 2008-04-17 2012-08-02 Wyeth Llc Methods for enhanced production of bone morphogenetic proteins
US8486699B2 (en) * 2008-05-23 2013-07-16 The United States Of America As Represented By The Secretary Of Agriculture Immortal unipotent porcine PICM-19H and PICM-19B stem cell lines
NZ597727A (en) 2009-07-31 2013-08-30 Baxter Int Cell culture medium for adamts protein expression
US8580554B2 (en) 2009-07-31 2013-11-12 Baxter International Inc. Method of producing a polypeptide or virus of interest in a continuous cell culture
EA202090067A3 (ru) 2010-07-08 2020-07-31 Баксалта Инкорпорейтид Способ получения рекомбинантного adamts13 в культуре клеток
TWI408228B (zh) 2010-10-29 2013-09-11 Univ Nat Chunghsing 用於生產一標的蛋白質的核酸建構物、重組型載體以及方法

Also Published As

Publication number Publication date
KR20180130587A (ko) 2018-12-07
EP4628093A2 (en) 2025-10-08
US20120035110A1 (en) 2012-02-09
HUE038193T2 (hu) 2018-09-28
JP2013538046A (ja) 2013-10-10
US9409971B2 (en) 2016-08-09
EA202090067A3 (ru) 2020-07-31
IL286298A (en) 2021-10-31
BR112013000515A2 (pt) 2016-05-17
HRP20250948T1 (hr) 2025-10-10
JP2013533748A (ja) 2013-08-29
IL273304B (en) 2021-09-30
CO6680636A2 (es) 2013-05-31
MX2013000165A (es) 2013-06-05
PL3064508T5 (pl) 2024-04-08
US20190085052A1 (en) 2019-03-21
DK2591094T3 (en) 2018-11-26
IL255327B (en) 2020-04-30
JP6138683B2 (ja) 2017-05-31
SG10201809632XA (en) 2018-12-28
MX353409B (es) 2018-01-11
SI3626736T1 (sl) 2025-10-30
NZ605403A (en) 2014-10-31
HRP20192089T4 (hr) 2023-04-28
EA201792340A3 (ru) 2018-07-31
KR20180099922A (ko) 2018-09-05
DK3064508T4 (da) 2023-04-11
KR20130091328A (ko) 2013-08-16
SG186935A1 (en) 2013-02-28
TWI670073B (zh) 2019-09-01
MX339632B (es) 2016-06-02
EP2590998B1 (en) 2017-11-15
CN108060154A (zh) 2018-05-22
PT2590998T (pt) 2018-02-13
PT3626736T (pt) 2025-08-11
SI2590998T1 (en) 2018-06-29
HUE11738351T2 (hu) 2019-03-28
TW201206953A (en) 2012-02-16
US20170008948A1 (en) 2017-01-12
AU2018200206A1 (en) 2018-04-05
PT3064508T (pt) 2019-12-05
KR101924120B1 (ko) 2018-11-30
HRP20181657T1 (hr) 2019-03-08
IL223929A (en) 2017-11-30
US8852888B2 (en) 2014-10-07
NZ605404A (en) 2014-08-29
EP2591094B1 (en) 2018-09-05
EA202090220A3 (ru) 2020-08-31
KR101894604B1 (ko) 2018-09-03
WO2012006591A1 (en) 2012-01-12
JP2017217004A (ja) 2017-12-14
SI2591094T1 (sl) 2018-12-31
ES2875772T3 (es) 2021-11-11
HRP20180136T1 (hr) 2018-04-06
PT2591094T (pt) 2018-11-20
US11780904B2 (en) 2023-10-10
AU2011274470B2 (en) 2015-08-13
EP3392271B1 (en) 2021-05-05
US20180044405A1 (en) 2018-02-15
SI3064508T2 (sl) 2023-05-31
CA2805557A1 (en) 2012-01-12
IL255327A0 (en) 2017-12-31
TW201204744A (en) 2012-02-01
EA029503B1 (ru) 2018-04-30
WO2012006594A1 (en) 2012-01-12
US20210115110A1 (en) 2021-04-22
IL286298B (en) 2022-08-01
SI3064508T1 (sl) 2019-12-31
EA035147B1 (ru) 2020-05-06
EA202090067A2 (ru) 2020-04-30
US9458222B2 (en) 2016-10-04
EP3064508B2 (en) 2023-03-15
PL3626736T3 (pl) 2025-10-13
PL2591094T3 (pl) 2019-02-28
AU2015207811B2 (en) 2017-10-19
US10100099B2 (en) 2018-10-16
TWI646972B (zh) 2019-01-11
HUE072809T2 (hu) 2025-12-28
KR102007773B1 (ko) 2019-08-06
EP3064508A1 (en) 2016-09-07
EA035066B1 (ru) 2020-04-23
EA201792340A2 (ru) 2018-02-28
CN103097409A (zh) 2013-05-08
EP2591094A1 (en) 2013-05-15
EP3626736A1 (en) 2020-03-25
IL273304A (en) 2020-04-30
HUE046443T2 (hu) 2020-03-30
AU2020203565A1 (en) 2020-06-18
AU2018200206B2 (en) 2020-05-28
PL3064508T3 (pl) 2020-02-28
TWI609890B (zh) 2018-01-01
US20120034674A1 (en) 2012-02-09
DK2590998T3 (en) 2018-02-12
JP2016025873A (ja) 2016-02-12
TW201900207A (zh) 2019-01-01
BR112013000515B1 (pt) 2021-11-03
KR20130091329A (ko) 2013-08-16
IL223930A (en) 2017-01-31
ES2664392T3 (es) 2018-04-19
AU2011274467B2 (en) 2015-01-15
TW201637665A (zh) 2016-11-01
DK3064508T3 (da) 2019-11-25
EP3909977A1 (en) 2021-11-17
EA201390082A1 (ru) 2013-06-28
AU2020203565B2 (en) 2021-09-30
JP5953502B2 (ja) 2016-07-20
AU2011274470A1 (en) 2013-01-24
CN103097522A (zh) 2013-05-08
US10822394B2 (en) 2020-11-03
EA201390080A1 (ru) 2013-06-28
EP3626736B1 (en) 2025-06-11
PL3392271T3 (pl) 2021-11-15
EP3392271B8 (en) 2021-06-16
AU2011274467A1 (en) 2013-01-24
JP6284919B2 (ja) 2018-02-28
CN107286235A (zh) 2017-10-24
AU2022200035A1 (en) 2022-01-20
PL2590998T3 (pl) 2018-05-30
ES2761692T5 (es) 2023-07-05
ES2761692T3 (es) 2020-05-20
AU2015207811A1 (en) 2015-08-20
MX2013000166A (es) 2013-06-05
EP3064508B1 (en) 2019-08-28
HRP20192089T1 (hr) 2020-03-20
US20150018525A1 (en) 2015-01-15
CO6690745A2 (es) 2013-06-17
CA2804275A1 (en) 2012-01-12
FI3626736T3 (fi) 2025-08-22
FI3064508T4 (fi) 2023-04-25
KR102027991B1 (ko) 2019-10-02
ES3037386T3 (en) 2025-10-01
ES2694518T3 (es) 2018-12-21
EA202090220A2 (ru) 2020-05-31
DK3626736T3 (da) 2025-08-18
TWI617575B (zh) 2018-03-11
EP4628093A3 (en) 2025-12-10
SG186936A1 (en) 2013-02-28
US20150056657A1 (en) 2015-02-26
BR112013000512A2 (pt) 2016-05-17
EP2590998A1 (en) 2013-05-15
US9834591B2 (en) 2017-12-05
EP3392271A1 (en) 2018-10-24

Similar Documents

Publication Publication Date Title
MX339632B (es) Metodo para producir adamts13 recombinante en cultivo celular.
Heidorn et al. Synthetic biology in cyanobacteria: engineering and analyzing novel functions
EA201270224A1 (ru) Среда для культивирования клеток для экспрессии белков adamts
MX2013003681A (es) Ácidos nucleicos manipulados y métodos de uso de los mismos.
MX2007002382A (es) Producci??n de anticuerpos anti-amiloides beta.
EA201591294A1 (ru) Рекомбинантный микроорганизм для применения в способе с повышенным выходом продукта
CY1110092T1 (el) ΠΑΡΑΣΚΕΥΗ TNFR-Fc
EA201171245A1 (ru) Модуляция acc-синтазы, улучшающая урожайность растений при условиях низкого содержания азота
WO2011091350A3 (en) Methods & compositions for improving protein production
BR112015001637A2 (pt) método usando microalgas para produção com eficiência elevada de astaxantina
WO2011075686A3 (en) Methods & compositions comprising heat shock proteins
PH12014501556A1 (en) Microorganism able to produce l-amino acid, and method for producing l-amino acid by using same
BR112012016437A2 (pt) fotobiorreator em meio fechado para a cultura de micro-organismos fotossintéticos.
AR087980A1 (es) Actividad de dnasa endogena para reducir el contenido de adn
WO2012142094A3 (en) Compositions and methods for increased ethanol production from biomass
EA201400877A1 (ru) Микроорганизмы, ферментирующие пентозы
UA97559C2 (uk) Комплекс нуклеїнової кислоти і композиція для доставки нуклеїнової кислоти
GB201105584D0 (en) Cancer methods
WO2010027505A3 (en) Decreasing rubisco content of algae and cyanobacteria cultivated in high carbon dioxide
MY180791A (en) Methods for obtaining a genetically modified plant or microbe and for increasing oil yield
GB201012011D0 (en) Fuel cell
MX2014013255A (es) Endoglucanasas con propiedades mejoradas.
Tan et al. Could Aerosol Dust Plume-derived Trace Metals and Inorganic Nutrient be Fueling the Recent Growth and Proliferation of Noctiluca scintillans Blooms in the Arabian Sea?
Khalil et al. Influence of micronutrients on the biological control of Pythium ultimum in a closed soilless system
Yokoyama Mycorrhizal symbiosis and evolution of myco-Heterotrophy in plants